Several phase 3 randomized studies of first-line therapy in patients with advanced ESCC have also demonstrated a positive association between PD-L1 expression and outcomes with PD-1 inhibitors plus chemotherapy2–4. Here, PDCD1 is linked to esophageal squamous cell carcinoma.